Prognostic discrimination using a 70-gene signature among patients with estrogen receptor-positive breast cancer and an intermediate 21-gene recurrence score

International Journal of Molecular Sciences

Volumn 14, Issue 12, 2013, Pages 23685-23699

  Ahn, Sung Gwe ^a   Lee, Hak Min ^a   Lee, Hak Woo ^a   Lee, Seung Ah ^b   Lee, Se Ra ^c   Leem, Sun Hee ^c   Jeong, Joon ^a   Chu, In Sun ^d  

^a Yonsei University College of Medicine   (South Korea)

^b Eulji General Hospital   (South Korea)

^c Dong A University   (South Korea)

^d Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

70 gene signature; AURKA; AURKB; BIRC5; Breast cancer; Estrogen receptor; FOXM1; Recurrence score

Indexed keywords

21 GENE RECURRENCE SCORE; 70 GENE SIGNATURE; ADULT; AGED; ARTICLE; AURKA GENE; AURKB GENE; BIRC5 GENE; CANCER PROGNOSIS; CELL PROLIFERATION; CLUSTER ANALYSIS; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; FOLLOW UP; FOXM1 GENE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC MARKER; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MOLECULAR GENETICS; MORTALITY; OVERALL SURVIVAL; SCORING SYSTEM; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PREDICTIVE VALUE; PROGNOSIS; TUMOR RECURRENCE; YOUNG ADULT;

AURORA KINASE; BIRC5 PROTEIN, HUMAN; ESTROGEN RECEPTOR; FORKHEAD TRANSCRIPTION FACTOR; FOXM1 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; TUMOR MARKER;

ADULT; AGED; AURORA KINASES; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLUSTER ANALYSIS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION PROFILING; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, ESTROGEN; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84889597716     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms141223685     Document Type: Article

References (28)

1. Millar, E.K.; Graham, P.H.; McNeil, C.M.; Browne, L.; O'Toole, S.A.; Boulghourjian, A.; Kearsley, J.H.; Papadatos, G.; Delaney, G.; Fox, C. et al. Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53. Br. J. Cancer 2011, 105, 272-280.
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005, 365, 1687-1717.
3. Howell, A.; Cuzick, J.; Baum, M.; Buzdar, A.; Dowsett, M.; Forbes, J.F.; Hoctin-Boes, G.; Houghton, J.; Locker, G.Y.; Tobias, J.S. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005, 365, 60-62.
4. Jakesz, R.; Jonat, W.; Gnant, M.; Mittlboeck, M.; Greil, R.; Tausch, C.; Hilfrich, J.; Kwasny, W.; Menzel, C.; Samonigg, H. et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005, 366, 455-462.
5. Paik, S.; Shak, S.; Tang, G.; Kim, C.; Baker, J.; Cronin, M.; Baehner, F.L.; Walker, M.G.; Watson, D.; Park, T. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 2004, 351, 2817-2826.
6. Paik, S.; Tang, G.; Shak, S.; Kim, C.; Baker, J.; Kim, W.; Cronin, M.; Baehner, F.L.; Watson, D.; Bryant, J.; et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 2006, 24, 3726-3734.
7. ClinicialTrials.gov Hormone therapy with or without combination chemotherapy in treating women who have undergone surgery for node-negative breast cancer (the TAILORx trial). Available online: http://clinicaltrials.gov/ct2/show/NCT00310180?term=tailorx&rank=1 (accessed on 29 August 2013).
8. Buyse, M.; Loi, S.; van't Veer, L.; Viale, G.; Delorenzi, M.; Glas, A.M.; d'Assignies, M.S.; Bergh, J.; Lidereau, R.; Ellis, P. et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J. Natl. Cancer Inst. 2006, 98, 1183-1192.
9. Van de Vijver, M.J.; He, Y.D.; van't Veer, L.J.; Dai, H.; Hart, A.A.; Voskuil, D.W.; Schreiber, G.J.; Peterse, J.L.; Roberts, C.; Marton, M.J. et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 2002, 347, 1999-2009.
10. Van't Veer, L.J.; Dai, H.; van de Vijver, M.J.; He, Y.D.; Hart, A.A.; Mao, M.; Peterse, H.L.; van der Kooy, K.; Marton, M.J.; Witteveen, A.T. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415, 530-536.
11. Bueno-de-Mesquita, J.M.; van Harten, W.H.; Retel, V.P.; van't Veer, L.J.; van Dam, F.S.; Karsenberg, K.; Douma, K.F.; van Tinteren, H.; Peterse, J.L.; Wesseling, J. et al. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: A prospective community-based feasibility study (RASTER). Lancet Oncol. 2007, 8, 1079-1087.
12. Mook, S.; Schmidt, M.K.; Viale, G.; Pruneri, G.; Eekhout, I.; Floore, A.; Glas, A.M.; Bogaerts, J.; Cardoso, F.; Piccart-Gebhart, M.J. et al. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res. Treat. 2009, 116, 295-302.
13. Mook, S.; Schmidt, M.K.; Weigelt, B.; Kreike, B.; Eekhout, I.; van de Vijver, M.J.; Glas, A.M.; Floore, A.; Rutgers, E.J.; van't Veer, L.J. The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. Ann. Oncol. 2010, 21, 717-722.
14. Weigelt, B.; Hu, Z.; He, X.; Livasy, C.; Carey, L.A.; Ewend, M.G.; Glas, A.M.; Perou, C.M.; van't Veer, L.J. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res. 2005, 65, 9155-9158.
15. Straver, M.E.; Glas, A.M.; Hannemann, J.; Wesseling, J.; van de Vijver, M.J.; Rutgers, E.J.; Vrancken Peeters, M.J.; van Tinteren, H.; van't Veer, L.J.; Rodenhuis, S. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res. Treat. 2010, 119, 551-558.
16. Clinicial Trials.gov Genetic testing or clinical assessment in determining the need for chemotherapy in women with breast cancer that involves no more than 3 lymph nodes. Available online: http://clinicaltrials.gov/ct2/show/NCT01272037?term=RxPONDER&rank=1 (accessed on 29 August 2013).
17. Halasi, M.; Gartel, A.L. FOX(M1) news-It is cancer. Mol. Cancer Ther. 2013, 12, 245-254.
18. Raychaudhuri, P.; Park, H.J. FoxM1: A master regulator of tumor metastasis. Cancer Res. 2011, 71, 4329-4333.
19. Wonsey, D.R.; Follettie, M.T. Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe. Cancer Res. 2005, 65, 5181-5189.
20. Chen, Y.J.; Dominguez-Brauer, C.; Wang, Z.; Asara, J.M.; Costa, R.H.; Tyner, A.L.; Lau, L.F.; Raychaudhuri, P. A conserved phosphorylation site within the forkhead domain of FoxM1B is required for its activation by cyclin-CDK1. J. Biol. Chem. 2009, 284, 30695-30707.
21. Pilarsky, C.; Wenzig, M.; Specht, T.; Saeger, H.D.; Grutzmann, R. Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. Neoplasia (N. Y.) 2004, 6, 744-750.
22. Bektas, N.; Haaf, A.; Veeck, J.; Wild, P.J.; Luscher-Firzlaff, J.; Hartmann, A.; Knuchel, R.; Dahl, E. Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in human breast cancer. BMC Cancer 2008, 8, 42.
23. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490, 61-70.
24. Wang, I.C.; Chen, Y.J.; Hughes, D.; Petrovic, V.; Major, M.L.; Park, H.J.; Tan, Y.; Ackerson, T.; Costa, R.H. Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol. Cell. Biol. 2005, 25, 10875-10894.
25. Sotiriou, C.; Wirapati, P.; Loi, S.; Harris, A.; Fox, S.; Smeds, J.; Nordgren, H.; Farmer, P.; Praz, V.; Haibe-Kains, B. et al. Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis. J. Natl. Cancer Inst. 2006, 98, 262-272.
26. Piccart-Gebhart, M.J. New developments in hormone receptor-positive disease. Oncologist 2010, 15, 18-28.
27. Chang, H.Y.; Nuyten, D.S.; Sneddon, J.B.; Hastie, T.; Tibshirani, R.; Sorlie, T.; Dai, H.; He, Y.D.; van't Veer, L.J.; Bartelink, H. et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc. Natl. Acad. Sci. USA 2005, 102, 3738-3743.
28. Harrell, F.E., Jr. General Aspects of Fitting Regression Models. In Regression Modeling Strategies; Springer: New York, NY, USA, 2001; pp. 11-40.